Abstract
ABSTRACTIn the last decade, a number of initiatives to define good practices for projects involving modeling and simulation have been put forward. No proposal for best practice in modeling and simulation, however, has been generally and consciously adopted in the pharmaceutical world. This perspective aims to highlight two recent proposals with respect to the use of modeling and simulation in the drug development and regulatory approval process. Both groups define Model-Informed Drug Discovery and Development (MID3) inclusively so as to potentially include the whole community of users of modeling and simulation. Applications in both communities (pharmacometrics and statistics) have many similarities in tools and methods to be used for model building, assumption testing, qualification versus available data, and sensitivity analysis, albeit with a different focus. Both communities are emphatic that the same good practices could apply across the wide range of modeling and simulation applications. A wider adoption of these common good practices in modeling and simulation across and between communities and practitioners is expected to enhance decision-making across drug research and development and regulatory environments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.